This review focuses on the activities that HIF-1 exerts in HCC, paying close attention to small-molecule inhibitors of the HIF-1 pathway as well as the recent progress of gene therapy aimed directly at HIF-1 genes. This evidence concerns the gene HIF1A and hepatocellular carcinoma.